When putting together your watch list, look for stocks with an 80 or higher RS Rating. Beam Therapeutics just cleared that benchmark with an upgrade from 78 to 81.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves.
Beam Therapeutics has climbed more than 5% past a 21.59 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Beam Therapeutics showed 0% EPS growth last quarter, while sales growth came in at -28%.
Beam Therapeutics holds the No. 310 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
